Shares of Ventyx Biosciences (NASDAQ:VTYX) traded flat on Tuesday, even after the company released promising top-line results ...

Parkinson’s disease affects more than 10 million people worldwide. Discover its causes, symptoms, and the latest innovations ...

Discover how Parkinson's disease begins in the gut, not the brain. Learn the early digestive warning signs that appear years ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

A team of researchers at UCLA has developed a high-tech diagnostic pen that can detect signs of Parkinson’s disease with over ...

Los Angeles Times readers give their thoughts on Bill Plaschke's poignant column on Parkinson's disease, the Dodgers and the ...

Bill Plaschke, the award-winning sports columnist and longtime "Around the Horn" panelist, announced his Parkinson's ...

MJFF co-founder and CEO Deborah W. Brooks read a letter of gratitude from Michael J. Fox for the support of the mission from ...

A new study suggests long-term exposure to chemicals used to keep fairways green may be tied to an increased risk of ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...